Atlas of Genetics and Cytogenetics in Oncology and Haematology

OPEN ACCESS JOURNAL INIST -CNRS

Gene Section Review

CLEC1B (C-Type Lectin Domain Family 1, Member B) Katsue Suzuki-Inoue Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, 409-3898 Chuo, Yamanashi, Japan (KSI)

Published in Atlas Database: November 2013 Online updated version : http://AtlasGeneticsOncology.org/Genes/CLEC1BID49856ch12p13.html DOI: 10.4267/2042/53964 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology

domain (CTLD) and belongs to the non-classical C- Abstract type lectins, which contain a CTLD homologous to Review on CLEC1B, with data on DNA/RNA, on a carbohydrate recognition domain but lack the the encoded and where the is consensus sequence for binding sugars and calcium implicated. (Colonna et al., 2000). CLEC-2 has a YxxL motif in its cytoplasmic tail, which is crucial for CLEC-2- Identity mediated signal transduction. This sequence is called hemi-ITAM, since it resembles the Other names: 1810061I13Rik, CLEC2, CLEC2B, immunoreceptor tyrosine-based activation motif PRO1384, QDED721 (ITAM, YxxL-(X)10-12-YxxL), which includes 2 HGNC (Hugo): CLEC1B YxxL motifs. CLEC-2 was first identified through a Location: 12p13.2 bioinformatic screen for C-type lectin-like molecules with immune functions. The gene DNA/RNA encoding CLEC-2 is located in the natural killer complex on 12 along with other Description C-type lectin-like receptors, including NKG2D, The gene is 982 bp in length and contains six LOX-1, and Dectin-1 (Sobanov et al., 2001). exons. Expression Transcription Organ: Highly expressed in bone marrow and In human, mouse, rabbit, rat, and bovine species, slightly expressed in liver. transcription produces 2-4 different mRNAs, Cell types: CLEC-2 protein is expressed at high including alternatively spliced variants and 1 levels in platelets/megakaryocytes and at low levels unspliced form. in sinusoidal endothelial cells (Chaipan et al., 2006) and Kupffer cells (Tang et al., 2010) in . In Pseudogene mice, CLEC-2 protein is highly expressed in No known pseudogenes. platelets/megakaryocytes, and is slightly expressed in other blood cells, including neutrophils, Protein monocytes, dendritic cells, NK cells, B cells (Chang et al., 2010; Mourao-Sa et al., 2011), and Description Kupffer cells (Tang et al., 2010). CLEC-2 is a 32-kDa (229 amino acids) type II trans-membrane receptor that belongs to C-type Localisation lectin superfamily. CLEC-2 has 1 C-type lectin-like Plasma membrane.

Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 457 CLEC1B (C-Type Lectin Domain Family 1, Member B) Suzuki-Inoue K

Schematic representation of the domain structure of CLEC-2. TM represents transmembrane region. Neck represents neck region. CTLD represents C-type lectin-like domain (Colonna et al., 2000; Watson et al., 2007; Wang et al., 2012).

Function platelets, severely compromises haemostasis and abrogates arterial thrombosis in mice (Bender et al., Separation of blood and lymphatic vessels 2013). CLEC-2 and GPVI, both of which generate during development activation signals depending on ITAMs and Podoplanin is also expressed on the surface of tyrosine kinases, play a complementary role in lymphatic endothelial cells, but not vascular thrombosis and haemostasis. endothelial cells. During organ development, a Maintenance of vascular integrity cluster of endothelial cells in the cardinal vein is CLEC-2 is involved in maintaining vascular committed to the lymphatic phenotype, and sprouts integrity in inflammation (Boulaftali et al., 2013) to form the primary lymphatic sacs from which a and high endothelial venules (HEVs) in lymph portion of the peripheral lymphatic vasculature is nodes upon lymphocyte transmigration (Herzog et generated by further centrifugal growth (Tammela al., 2013). Podoplanin is expressed on fibroblastic and Alitalo, 2010). reticular cells, which surround HEVs. At this stage, platelets are activated by an Upon lymphocyte transmigration, platelets association between CLEC-2 in the platelets and extravasate to the perivenular space of HEVs and podoplanin in the lymphatic endothelial cells, interact with podoplanin. which inhibits the growth and migration of Local release of sphingosine-1-phosphate after lymphatic endothelial cells and facilitates the CLEC-2-podoplanin-mediated platelet activation is separation of blood and lymphatic vessels. critical for HEV integrity during immune CLEC-2-deficient mice show blood-filled responses. lymphatic vessels and severe edema due to Antigen presentation lymphatic dysfunction (Bertozzi et al., 2010; CLEC-2 is also expressed in dendritic cells (DCs) Suzuki-Inoue et al., 2010; Finney et al., 2011). in mice. Associations between CLEC-2 in DCs and One controversial theory proposes that granule podoplanin in lymphatic endothelial and contents released from activated platelets inhibit the fibroblastic reticular cells in the lymph nodes function of lymphatic endothelial cells (Osada et facilitates DC entry into the lymphatics as well as al., 2012). movement to and within the lymph nodes, thereby Thrombus formation reducing T cell priming. Thrombus formation under flow conditions has CLEC-2 engagement of podoplanin was found to been reported to be impaired in CLEC-2-deficient be necessary for DCs to spread and migrate along blood. In vivo thrombus formation is also inhibited stromal surfaces, and was sufficient to induce in antibody-induced CLEC-2-deficient mice (May membrane protrusions through Vav and Rac1 et al., 2009) or bone marrow chimeric mice activation (Acton et al., 2012). deficient in CLEC-2 (Suzuki-Inoue et al., 2010). HIV transmission These findings suggest that CLEC-2 is involved in Previous reports indicate that platelets capture and the stabilization of thrombus formation under flow transfer infectious HIV-1 via DC-SIGN and CLEC- conditions, although the precise mechanism by 2, possibly facilitated HIV-1 dissemination in which this occurs has not yet been elucidated. infected patients (Suzuki-Inoue et al., 2011). Combined in vivo depletion of CLEC-2 and CLEC-2 does not directly bind to the viral envelope glycoprotein VI (GPVI), a collagen receptor in , but to podoplanin incorporated into the

Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 458 CLEC1B (C-Type Lectin Domain Family 1, Member B) Suzuki-Inoue K

HIV particles released from HEK-293T cells growth. In an experimental model of metastasis in (Chaipan et al., 2010). mice, an anti-podoplanin blocking antibody This mechanism does not seem to be important for significantly inhibited the number of tumour-cell viral dispersion in vivo since podoplanin is not containing metastatic lung nodules that expressed expressed on T cells, which are the major HIV podoplanin, implying that CLEC-2/podoplanin may target. be a promising target protein for anti-metastatic Phagocytosis and cytokine production drugs (Kato et al., 2008). CLEC-2 is expressed in dendritic cells, NK cells, B cells, neutrophils, and monocytes, in addition to Various diseases platelets (Kerrigan et al., 2009; Chang et al., 2010; Note Mourao-Sa et al., 2011). Murine CLEC-2 in No implication in any specific diseases in human neutrophils mediates the phagocytosis of anti- has been reported. CLEC-2 antibody-coated beads. Moreover, neutrophils stimulated by rhodocytin produce References proinflammatory cytokines such as TNF-α Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis depending on CLEC-2, but not respiratory burst of tumor cells by natural killer cells in mice is impeded by (Kerrigan et al., 2009). CLEC-2 ligation in platelets. Cancer Res. 1999 Mar 15;59(6):1295-300 macrophages and DCs selectively up-regulates Colonna M, Samaridis J, Angman L. Molecular production of IL-10, an anti-inflammatory cytokine, characterization of two novel C-type lectin-like receptors, by Toll-like receptor stimulation. Although the one of which is selectively expressed in human dendritic physiological relevance of these phenomena has not cells. Eur J Immunol. 2000 Feb;30(2):697-704 been determined, CLEC-2 is expressed in myeloid Sobanov Y, Bernreiter A, Derdak S, Mechtcheriakova D, cells and may be able to modulate the inflammatory Schweighofer B, Düchler M, Kalthoff F, Hofer E. A novel response in vivo. cluster of lectin-like receptor expressed in monocytic, dendritic and endothelial cells maps close to Homology the NK receptor genes in the human NK gene complex. Eur J Immunol. 2001 Dec;31(12):3493-503 Among 226-229 amino acids of 5 species' (human, mouse, rat, rabbit, and bovine) CLEC-2, there are Chaipan C, Soilleux EJ, Simpson P, Hofmann H, 129 positions with 100% sequence conservation, 36 Gramberg T, Marzi A, Geier M, Stewart EA, Eisemann J, Steinkasserer A, Suzuki-Inoue K, Fuller GL, Pearce AC, positions with 80% sequence conservation, and 44 Watson SP, Hoxie JA, Baribaud F, Pöhlmann S. DC-SIGN positions with 60% sequence conservation. Human and CLEC-2 mediate human immunodeficiency virus type CLEC-2 is 62% identical to mouse CLEC-2, and 1 capture by platelets. J Virol. 2006 Sep;80(18):8951-60 70% to rabbit CLEC-2. Suzuki-Inoue K, Fuller GL, García A, Eble JA, Pöhlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing Mutations GD, Theakston RD, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VL, Ozaki Y, Watson SP. A novel Syk- Note dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006 Jan 15;107(2):542-9 No known mutations. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y. Involvement Implicated in of the snake toxin receptor CLEC-2, in podoplanin- mediated platelet activation, by cancer cells. J Biol Chem. Haematogenous tumour metastasis 2007 Sep 7;282(36):25993-6001 Note Watson AA, Brown J, Harlos K, Eble JA, Walter TS, CLEC-2 has been identified as a receptor for a O'Callaghan CA. The crystal structure and mutational platelet activating snake venom, rhodocytin binding analysis of the extracellular domain of the platelet- activating receptor CLEC-2. J Biol Chem. 2007 Feb (Suzuki-Inoue et al., 2006). Podoplanin is a type I 2;282(5):3165-72 transmembrane sialomucin-like glycoprotein, and is Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt identified as the endogenous ligand for CLEC-2 AY, Fenton-May AE, Johnson LA, Jackson DG, Watson (Suzuki-Inoue et al., 2007; Christou et al., 2008). It SP, O'Callaghan CA. Renal cells activate the platelet is expressed on the surface of certain types of receptor CLEC-2 through podoplanin. Biochem J. 2008 tumour cells, where it causes aggregation of Apr 1;411(1):133-40 platelets in the blood stream, facilitating Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, haematogenous tumour metastasis. Platelet Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, aggregation surrounding tumour cells is considered Inoue O, Ozaki Y, Narimatsu H. Molecular analysis of the pathophysiological binding of the platelet aggregation- to protect the tumour cells from shear stress and inducing factor podoplanin to the C-type lectin-like receptor NK cells (Nieswandt et al., 1999) in the blood CLEC-2. Cancer Sci. 2008 Jan;99(1):54-61 stream and provide scaffolding for tumour cell Kerrigan AM, Dennehy KM, Mourão-Sá D, Faro-Trindade I, nests. Growth factors released from activated Willment JA, Taylor PR, Eble JA, Reis e Sousa C, Brown platelets stimulate angiogenesis and/or tumour GD. CLEC-2 is a phagocytic activation receptor expressed

Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 459 CLEC1B (C-Type Lectin Domain Family 1, Member B) Suzuki-Inoue K

on murine peripheral blood neutrophils. J Immunol. 2009 Haemost. 2011 Jul;9 Suppl 1:44-55 Apr 1;182(7):4150-7 Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble J, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elvers M, Nieswandt B. CLEC-2 is an essential platelet- Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, activating receptor in hemostasis and thrombosis. Blood. Gonzalez SF, Graham DB, Chang J, Peters A, Woodruff 2009 Oct 15;114(16):3464-72 M, Kim YA, Swat W, Morita T, Kuchroo V, Carroll MC, Kahn ML, Wucherpfennig KW, Turley SJ. Podoplanin-rich Bertozzi CC, Schmaier AA, Mericko P, Hess PR, Zou Z, stromal networks induce dendritic cell motility via activation Chen M, Chen CY, Xu B, Lu MM, Zhou D, Sebzda E, of the C-type lectin receptor CLEC-2. Immunity. 2012 Aug Santore MT, Merianos DJ, Stadtfeld M, Flake AW, Graf T, 24;37(2):276-89 Skoda R, Maltzman JS, Koretzky GA, Kahn ML. Platelets regulate lymphatic vascular development through CLEC-2- Finney BA, Schweighoffer E, Navarro-Núñez L, Bénézech SLP-76 signaling. Blood. 2010 Jul 29;116(4):661-70 C, Barone F, Hughes CE, Langan SA, Lowe KL, Pollitt AY, Mourao-Sa D, Sheardown S, Nash GB, Smithers N, Reis e Chaipan C, Steffen I, Tsegaye TS, Bertram S, Glowacka I, Sousa C, Tybulewicz VL, Watson SP. CLEC-2 and Syk in Kato Y, Schmökel J, Münch J, Simmons G, Gerardy- the megakaryocytic/platelet lineage are essential for Schahn R, Pöhlmann S. Incorporation of podoplanin into development. Blood. 2012 Feb 16;119(7):1747-56 HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor Osada M, Inoue O, Ding G, Shirai T, Ichise H, Hirayama K, CLEC-2. Retrovirology. 2010 May 19;7:47 Takano K, Yatomi Y, Hirashima M, Fujii H, Suzuki-Inoue K, Ozaki Y. Platelet activation receptor CLEC-2 regulates Chang CH, Chung CH, Hsu CC, Huang TY, Huang TF. A blood/lymphatic vessel separation by inhibiting novel mechanism of cytokine release in phagocytes proliferation, migration, and tube formation of lymphatic induced by aggretin, a snake venom C-type lectin protein, endothelial cells. J Biol Chem. 2012 Jun through CLEC-2 ligation. J Thromb Haemost. 2010 22;287(26):22241-52 Nov;8(11):2563-70 Wang L, Ren S, Zhu H, Zhang D, Hao Y, Ruan Y, Zhou L, Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura Lee C, Qiu L, Yun X, Xie J. Structural and functional K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura conservation of CLEC-2 with the species-specific K, Shin Y, Hirashima M, Ozaki Y. Essential in vivo roles of regulation of transcript expression in evolution. Glycoconj the C-type lectin receptor CLEC-2: embryonic/neonatal J. 2012 Aug;29(5-6):335-45 lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of Bender M, May F, Lorenz V, Thielmann I, Hagedorn I, CLEC-2-deficient platelets. J Biol Chem. 2010 Aug Finney BA, Vögtle T, Remer K, Braun A, Bösl M, Watson 6;285(32):24494-507 SP, Nieswandt B. Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely Tammela T, Alitalo K. Lymphangiogenesis: Molecular compromises hemostasis and abrogates arterial mechanisms and future promise. Cell. 2010 Feb thrombosis in mice. Arterioscler Thromb Vasc Biol. 2013 19;140(4):460-76 May;33(5):926-34 Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, Grant D, Boulaftali Y, Hess PR, Getz TM, Cholka A, Stolla M, Solloway M, Parker L, Ye W, Forrest W, Ghilardi N, Mackman N, Owens AP 3rd, Ware J, Kahn ML, Bergmeier Oravecz T, Platt KA, Rice DS, Hansen GM, Abuin A, W. Platelet ITAM signaling is critical for vascular integrity in Eberhart DE, Godowski P, Holt KH, Peterson A, inflammation. J Clin Invest. 2013 Feb 1;123(2):908-16 Zambrowicz BP, de Sauvage FJ. A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol. Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel 2010 Jul;28(7):749-55 JM, Pan Y, Sheng M, Yago T, Silasi-Mansat R, McGee S, May F, Nieswandt B, Morris AJ, Lupu F, Coughlin SR, Mourão-Sá D, Robinson MJ, Zelenay S, Sancho D, McEver RP, Chen H, Kahn ML, Xia L. Podoplanin Chakravarty P, Larsen R, Plantinga M, Van Rooijen N, maintains high endothelial venule integrity by interacting Soares MP, Lambrecht B, Reis e Sousa C. CLEC-2 with platelet CLEC-2. Nature. 2013 Oct 3;502(7469):105-9 signaling via Syk in myeloid cells can regulate inflammatory responses. Eur J Immunol. 2011 This article should be referenced as such: Oct;41(10):3040-53 Suzuki-Inoue K. CLEC1B (C-Type Lectin Domain Family 1, Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation Member B). Atlas Genet Cytogenet Oncol Haematol. 2014; receptor CLEC-2: from discovery to prospects. J Thromb 18(7):457-460.

Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 460